Does This Email Message from KVK Tech Violate FDA Regulations?

Today, I received an email message from KVK Tech - a generic drug manufacturer located in my my hometown of Newtown, PA - regarding a gift to Stanford ' s Department of Bariatric and Minimally Invasive Surgery (see below; ignore that the email has the wrong date on it - you can ' t expect a drug company to have good copy editors, can you?). It talks about obesity in the U.S.At the end of the email, in the " About KVK Tech " section, it mentions that it manufactures and distributes Lomaira, which is a drug to treat obesity. Unfortunately, KVK Tech does not mention the Important Safety Information (ISI) whenever a drug company mention a brand name drug and its indication in the same communication.I believe, therefore, that this email violates FDA regulations. I ' ve passed this on via email to the FDA ' s BadAd program, which I am not sure still exists. Not being a healthcare professional, I don ' t have much standing with the FDA in any case.So, what do you think? Violative or not?
Source: Pharma Marketing Blog - Category: Pharmaceuticals Tags: FDA KVK Tech Obesity drugs regulations Source Type: blogs